SILAC analysis of imatinib-treated EoL-1 cells
PSDB ID . | pTyr sites . | Peptide . | Fold reduction, control/treated . | Found in Bcr-Abl signature . |
|---|---|---|---|---|
| Peptides that are less abundant after imatinib treatment | ||||
| Adaptor/scaffold | ||||
| Shc | 427 | ELFDDPSyVNVQNLDK | > 10 | Yes* |
| Protein kinase | ||||
| ERK2 | 187 | VADPDHDHTGFLTEyVATR | > 10 | No |
| FIP1L1 | 98 | TGAPQYGSyGTAPVNLNIK | > 2 | No |
| PDGFR-α | 742 | QADTTQyVPMLER | > 2 | No |
| PDGFR-α | 762 | SLyDRPASYK | > 2 | No |
| PDGFR-α | 762, 768 | SLyDRPASyK | > 10 | No |
| Lipid kinase | ||||
| PIK3CB | 504, 505 | KQPYyyPPFDK | > 10 | No |
| PIK3R1 | 467 | SREYDRLyEEYTR | > 2 | No |
| Lipid phosphatase | ||||
| SHIP | 914 | APPCSGSSITEIINPNyMGVGPFGPPMPLHVK | > 2 | No |
| SHIP-2 | 986 | NSFNNPAyYVLEGVPHQLLPPEPPSPAR | > 5 | Yes* |
| Transcription factor | ||||
| STAT5A | 694 | AVDGyVKPQIK | > 5 | No |
| Other | No | |||
| Calmodulin | 100 | VFDKDGNGyISAAELR | > 2 | No |
| hnRNP-I | 127 | GQPIyIQFSNHK | > 2 | No |
| Peptide intensities remaining unchanged after imatinib treatment | ||||
| Protein kinase | ||||
| Cdc2 | 15 | IGEGTyGVVYK | 1.89 | No |
| DYRK1A | 321 | IYQyIQSR | 1.23 | No |
| GSK3-β | 216 | GEPNVSyICSR | 0.81 | No |
| PRP4 | 849 | LCDFGSASHVADNDITPyLVSR | 0.96 | No |
| Syk | 323 | QESTVSFNPyEPELAPWAADKGPQR | 0.70 | No |
| Lipid kinase | ||||
| PIK3CD | 485 | SNPNTDSAAALLICLPEVAPHPVYyPALEK | 1.39 | No |
| PIK3CD | 524 | GSGELyEHEKDLVWK | 1.20 | No |
| PIK3R1 | 580 | DQyLMWLTQK | 1.12 | No |
| PIK3R2 | 453 | VYHQQyQD | 1.72 | No |
| Protein phosphatase | ||||
| SHP-2 | 62 | IQNTGDyYDLYGGEK | 1.33 | No |
| SHP-2 | 580 | EDSARVyENVGLMQQQK | 1.33 | No |
| Other | ||||
| PAG | 317 | SREEDPTLTEEEISAMySSVNKPGQLVNK | 0.92 | No |
| PAG | 417 | ENDyESISDLQQGR | 0.61 | No |
| PSMB6 | 59 | TTTGSyIANR | 1.25 | No |
| THTP | 30 | LQELGGTLEyR | 0.68 | No |
PSDB ID . | pTyr sites . | Peptide . | Fold reduction, control/treated . | Found in Bcr-Abl signature . |
|---|---|---|---|---|
| Peptides that are less abundant after imatinib treatment | ||||
| Adaptor/scaffold | ||||
| Shc | 427 | ELFDDPSyVNVQNLDK | > 10 | Yes* |
| Protein kinase | ||||
| ERK2 | 187 | VADPDHDHTGFLTEyVATR | > 10 | No |
| FIP1L1 | 98 | TGAPQYGSyGTAPVNLNIK | > 2 | No |
| PDGFR-α | 742 | QADTTQyVPMLER | > 2 | No |
| PDGFR-α | 762 | SLyDRPASYK | > 2 | No |
| PDGFR-α | 762, 768 | SLyDRPASyK | > 10 | No |
| Lipid kinase | ||||
| PIK3CB | 504, 505 | KQPYyyPPFDK | > 10 | No |
| PIK3R1 | 467 | SREYDRLyEEYTR | > 2 | No |
| Lipid phosphatase | ||||
| SHIP | 914 | APPCSGSSITEIINPNyMGVGPFGPPMPLHVK | > 2 | No |
| SHIP-2 | 986 | NSFNNPAyYVLEGVPHQLLPPEPPSPAR | > 5 | Yes* |
| Transcription factor | ||||
| STAT5A | 694 | AVDGyVKPQIK | > 5 | No |
| Other | No | |||
| Calmodulin | 100 | VFDKDGNGyISAAELR | > 2 | No |
| hnRNP-I | 127 | GQPIyIQFSNHK | > 2 | No |
| Peptide intensities remaining unchanged after imatinib treatment | ||||
| Protein kinase | ||||
| Cdc2 | 15 | IGEGTyGVVYK | 1.89 | No |
| DYRK1A | 321 | IYQyIQSR | 1.23 | No |
| GSK3-β | 216 | GEPNVSyICSR | 0.81 | No |
| PRP4 | 849 | LCDFGSASHVADNDITPyLVSR | 0.96 | No |
| Syk | 323 | QESTVSFNPyEPELAPWAADKGPQR | 0.70 | No |
| Lipid kinase | ||||
| PIK3CD | 485 | SNPNTDSAAALLICLPEVAPHPVYyPALEK | 1.39 | No |
| PIK3CD | 524 | GSGELyEHEKDLVWK | 1.20 | No |
| PIK3R1 | 580 | DQyLMWLTQK | 1.12 | No |
| PIK3R2 | 453 | VYHQQyQD | 1.72 | No |
| Protein phosphatase | ||||
| SHP-2 | 62 | IQNTGDyYDLYGGEK | 1.33 | No |
| SHP-2 | 580 | EDSARVyENVGLMQQQK | 1.33 | No |
| Other | ||||
| PAG | 317 | SREEDPTLTEEEISAMySSVNKPGQLVNK | 0.92 | No |
| PAG | 417 | ENDyESISDLQQGR | 0.61 | No |
| PSMB6 | 59 | TTTGSyIANR | 1.25 | No |
| THTP | 30 | LQELGGTLEyR | 0.68 | No |
Peptides common to the Bcr-Abl signature.